Affiliation:
1. CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety National Center for Nanoscience and Technology (NCNST) Beijing People's Republic of China
2. University of Chinese Academy of Sciences (UCAS) Beijing People's Republic of China
Abstract
AbstractOwing to the breakthroughs in the prevention and control of the COVID‐19 pandemic, messenger RNA (mRNA)‐based vaccines have emerged as promising alternatives to conventional vaccine approaches for infectious disease prevention and anticancer treatments. Advantages of mRNA vaccines include flexibility in designing and manipulating antigens of interest, scalability in rapid response to new variants, ability to induce both humoral and cell‐mediated immune responses, and ease of industrialization. This review article presents the latest advances and innovations in mRNA‐based vaccines and their clinical translations in the prevention and treatment of infectious diseases or cancers. We also highlight various nanoparticle delivery platforms that contribute to their success in clinical translation. Current challenges related to mRNA immunogenicity, stability, and in vivo delivery and the strategies for addressing them are also discussed. Finally, we provide our perspectives on future considerations and opportunities for applying mRNA vaccines to fight against major infectious diseases and cancers.This article is categorized under:
Therapeutic Approaches and Drug Discovery > Emerging Technologies
Therapeutic Approaches and Drug Discovery > Nanomedicine for Infectious Disease
Biology‐Inspired Nanomaterials > Lipid‐Based Structures
Funder
Chinese Academy of Sciences
Subject
Biomedical Engineering,Medicine (miscellaneous),Bioengineering
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献